TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01118013
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02464046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
Study: NCT03723551
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered with SOC in accordance with local practice and applicable treatment guidelines.
Study: NCT04531150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive placebo tablets
Study: NCT02894385
Drug: BAY1841788
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
Study: NCT02912559
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02912559
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03441789
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle foam applied to affected areas once daily
Study: NCT03328104
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 440 mg/m2 IV x Day 1-5
Study: NCT03792035
Drug: Tongxinluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tid, po.
Study: NCT03792035
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: tid, po.
Study: NCT00676429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as oral solution, individually titrated
Study: NCT04581772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT01732926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally twice daily
Study: NCT02490878
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02544113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal transplant immunosuppression
Study: NCT01023308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered 3x week ( 2 weeks on 1 week off)
Study: NCT00337415
Drug: MK0354
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02734953
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
Study: NCT03728153
Drug: Fluoxetine 20 MG Oral Tablet
Normalized name: fluoxetine 20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing for 90 days
Study: NCT01087723
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04017949
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cc (40 mg) of a corticosteroid (kenalog) is given
Study: NCT01074437
Drug: Prednisolone (Corticosteroid)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
Study: NCT01074437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid placebo will be given during the two month treatment trial.
Study: NCT03896620
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of chemotherapy.
Study: NCT03321877
Drug: Change to dose of patient's regular medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction of the drug each patient was already taking
Study: NCT03172741
Drug: Medical Marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-gram marijuana cigarette smoked once per day for 3 months
Study: NCT03172741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching 1 gram placebo cigarette smoked once per day for 3 months
Study: NCT01281553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
Study: NCT03585114
Drug: [F-18] DCFPyL
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
Study: NCT04494425
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
Study: NCT02701582
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered
Study: NCT03270579
Drug: [18F]JNJ-64511070
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.
Study: NCT02343978
Drug: KWA-0711
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03199261
Drug: rE-4 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
Study: NCT02396498
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using cisplatin in HIPEC plus oral S-1
Study: NCT02995733
Drug: PARTICS using QVAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient takes inhaled corticosteroid at the time of rescue inhaler use
Study: NCT00981929
Drug: Omeprazole, losartan, caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole 25 mg losartan 200 mg caffeine
Study: NCT00981929
Drug: Tramadol, omeprazole, losartan, caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
Study: NCT00209222
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT04044976
Drug: Caffeine Citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
Study: NCT00209222
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT02091206
Drug: GWP42003-P 5 mg/kg/day Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Study: NCT02026973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02005029
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02005029
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02307162
Drug: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase 3 and 4 Inhibitor
Study: NCT03842696
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
Study: NCT03842696
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
Study: NCT05191186
Drug: Grass pollen extract - Alutard Phleum pratense, ALK
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection in lymph node
Study: NCT04501107
Drug: Administration of US-approved Humalog® (IMP3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of IMP3 during a 12-hour euglycaemic clamp.
Study: NCT04501107
Drug: Administration of EU-approved Humalog® (IMP4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of IMP4 during a 12-hour euglycaemic clamp.
Study: NCT02642159
Drug: Antihyperglycemic Drug
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
Study: NCT01961804
Drug: Reversion
Normalized name: Reversion Acne Control Toner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of prothrombin complex concentrates: KANOKAD before CT Scan
Study: NCT01039558
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
Study: NCT01370161
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed.
Study: NCT03595826
Drug: Neurostimulant pharmaceutical drugs
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
Study: NCT02690025
Drug: ZP1848
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03742232
Drug: PEG3350
Normalized name: PEG3350
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
Study: NCT00105521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to sarizotan will be administered twice daily.
Study: NCT01536535
Drug: Oral Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with oral corticosteroids
Study: NCT03456843
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
Study: NCT00094497
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02003664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
Study: NCT01485991
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
Study: NCT02091206
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT02091206
Drug: GWP42003-P 10 mg/kg/day Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Study: NCT01819818
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
Study: NCT02307162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy solution
Study: NCT01475370
Drug: OCV-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose.
Study: NCT02538471
Drug: Study Drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
Study: NCT02131155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT01887418
Drug: QuickShot™ - 50 mg Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: QuickShot™ for the delivery of testosterone
Study: NCT01887418
Drug: QuickShot™ - 100 mg Treatment A
Approvals — FDA: no, EMA: no, PMDA: no
Description: QuickShot™ for the delivery of testosterone
Study: NCT01887418
Drug: Delatestryl 200 mg IM Treatment C
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care
Study: NCT04611724
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
Study: NCT04761341
Drug: NUTROF TOTAL
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 per day over a course of 3 months
Study: NCT03412513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo po daily for 8 weeks to Placebo comparator group.
Study: NCT02527863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Unikalk pr day for 1 day
Study: NCT00730392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
Study: NCT03604653
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/m2@T0
Study: NCT03663543
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Study: NCT00433498
Drug: pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg daily oral tablet taken for a maximum of 2 years
Study: NCT01178281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
Study: NCT02646189
Drug: REP 2139-Ca
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
Study: NCT02977780
Drug: QBS10072S
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBS10072S administered intravenously
Study: NCT00243217
Drug: SPM 936
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02160678
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
Study: NCT02160678
Drug: Tazorac Cream, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
Study: NCT00626158
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
Study: NCT02706834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-828 placebo-matching oral solution
Study: NCT03398434
Drug: MAA868
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MAA868 doses, single administration, subcutaneous,
Study: NCT03362047
Drug: Riciguat Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered 12 weeks Riciguat
Study: NCT02223507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00255515
Drug: conventional treatment for schizophrenia
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: various standard therapies
Study: NCT00609245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
Study: NCT01535196
Drug: Vigantol oil and MCT oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
Study: NCT00218075
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01631825
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT02068352
Drug: OPA-15406
Normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPA-15406 topical ointment
Study: NCT00119314
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01141153
Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent
Study: NCT03986944
Drug: Placebo capsule to match Add-back capsule
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT01233492
Drug: boron phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03327051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match omeprazole
Study: NCT01399684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study: NCT00546702
Drug: Insuline Glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04073849
Drug: EPOGEN® (epoetin alfa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug
Study: NCT00733551
Drug: GSK962040
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
Study: NCT00355602
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00355602
Drug: Coamoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00355602
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02608697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02186496
Drug: CKD-330 8/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03817346
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator single ascending dose
Study: NCT02802683
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: continous infusion of normal saline
Study: NCT00658697
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Study: NCT01641289
Drug: No Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.
Study: NCT01963442
Drug: Placebo (for Augmentin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets 3 times a day for 5 days from Day 3
Study: NCT01963442
Drug: Beta-Lactams
Normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered from Day 0 to Day 3